证券代码：603231 证券简称：索宝蛋白 公告编号：2026-002 宁波索宝蛋白科技股份有限公司 关于 2025 年中期利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：A 股每 10 股派发现金红利 0.70 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 一、利润分配方案内容 （一）利润分配方案的具体内容 根据宁波索宝蛋白科技股份有限公司（以下简称"公司"）2025 年三季度 财务报表（未经审计），2025 年前三季度公司合并报表实现归属于母公司股东 的净利润 146,687,897.41 元，母公司未分配利润 14,661,604.63 元。为进一步 回馈投资者，兼顾投资者短期收益和长期利益，与股东积极分享经营发展成果， 经董事会决议，本次中期利润分配方案如下： 1、公司拟以实施权益分派股 ...

Group 1 - The core point of the article is that Sobao Protein (603231) reported a total of 16,133 shareholders as of December 20, 2025 [1]

证券代码：603231 证券简称：索宝蛋白 公告编号：2025-036 宁波索宝蛋白科技股份有限公司 关于开立募集资金专项账户并签订募集资金存 储四方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意宁波索宝蛋白科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2023]1851号），同意宁波索宝 蛋白科技股份有限公司（以下简称"公司"）首次公开发行股票的注册申请，并 经上海证券交易所同意，公司于2023年12月15日首次向社会公众公开发行人民币 普通股（A股）4,786.48万股，发行价格为每股人民币21.29元，募集资金总额为 人民币101,904.16万元，扣除发行费用（不含税）人民币3,958.59万元后，实际 募集资金净额为人民币97,945.57万元。 以上募集资金于2023年12月8日全部到位，由大华会计师事务所（特殊普通 合伙）审验确认，并由其出具了《验资报告》（大华验字[2023]000701号）。 二、《募集资金专户存储四 ...

Group 1 - The core business of the company is the research, production, and sales of soybean protein series products [1] - The main product, soybean protein, is used in the production of health supplement protein powder [1] - The company has a stake in Shandong Meijike Biotechnology Co., Ltd., which focuses on the research, production, and sales of health food [1]

Group 1 - The core point of the article is that as of December 10, 2025, the number of shareholders for the company Suobao Protein is projected to be 16,079 [2]

Core Viewpoint - The company, Suobao Protein, announced a share reduction by its shareholders, Jinan Fosun and its concerted action party, Ningbo Fosun, which indicates a strategic shift in their investment position [1] Group 1: Shareholder Actions - Jinan Fosun and Ningbo Fosun collectively reduced their holdings by 298,000 shares [1] - The shareholding percentage decreased from 14.08% to 13.92%, crossing a 1% threshold [1]

Group 1 - The core point of the announcement is that Jinan Caijin Fuxing Weishi Equity Investment Fund Partnership and its action-in-concert party, Shanghai Fuxing Chuangfu Investment Management Co., Ltd., have reduced their shareholding in Ningbo Suobao Protein Technology Co., Ltd. by 298,000 shares, decreasing their total shareholding from 26,946,092 shares to 26,648,092 shares, which is a reduction from 14.08% to 13.92% of the total share capital [1][2] - The share reduction occurred between December 4 and December 5, 2025, and it triggered a change that crossed the 1% threshold [1] - The announcement confirms that this change in shareholding will not lead to a change in the controlling shareholder or actual controller of the company [2] Group 2 - The equity change does not require the disclosure of an equity change report and complies with relevant laws and regulations, including the Securities Law of the People's Republic of China [2] - The equity change aligns with the previously disclosed reduction plan and does not trigger a mandatory tender offer or involve any changes in funding sources [2] - The company will continue to monitor the progress of the reduction plan and fulfill its information disclosure obligations as required [2]

1.身份类别 | | □控股股东/实际控制人及其一致行动人 ☑其他 | | --- | --- | | | 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 重要内容提示： 权益变动方向 比例增加□ 比例减少☑ 权益变动前合计比例 14.08% 权益变动后合计比例 13.92% 本次变动是否违反已作出的承 诺、意向、计划 是□ 否☑ 是否触发强制要约收购义务 是□ 否☑ 二、 权益变动触及 1%刻度的基本情况 宁波索宝蛋白科技股份有限公司（以下简称"公司"）于 2025 年 12 月 8 日收到股东济南财金复星惟实股权投资基金合伙企业（有限合伙）（以下简称"济 南复星"）及其一致行动人上海复星创富投资管理股份有限公司－宁波梅山保税 港区复星惟盈股权投资基金合伙企业（有限合伙）（以下简称"宁波复星"）出具 的《关于减持宁波索宝蛋白科技股份有限公司股份跨越 1%整数倍的告知函》。于 2025 年 12 月 4 日-12 月 5 日期间，济南复星、宁波 ...

Core Viewpoint - The company, Suobao Protein (603231.SH), announced a significant share reduction by its shareholders, which may impact the stock's market perception and investor confidence [1] Group 1: Shareholder Actions - The shareholders, Jinan Caijin Fuxing Weishi Equity Investment Fund Partnership and Shanghai Fuxing Chuangfu Investment Management Co., reduced their holdings in Suobao Protein by a total of 298,000 shares [1] - The total number of shares held by Jinan Fuxing and Ningbo Fuxing decreased from 26.9461 million shares to 26.6481 million shares [1] - The percentage of total shares held by these shareholders fell from 14.08% to 13.92%, crossing a 1% threshold [1]

Core Viewpoint - The company, Suzhou Sobo Protein Technology Co., Ltd. (603231.SH), announced a share reduction by major shareholders, which has resulted in a decrease in their ownership percentage [1] Group 1: Shareholder Actions - The shareholders, Jinan Caijin Fuxing Weishi Equity Investment Fund Partnership (Limited Partnership) and Shanghai Fuxing Chuangfu Investment Management Co., Ltd., notified the company about their share reduction [1] - Between December 4 and December 5, 2025, the shareholders collectively reduced their holdings by 298,000 shares through centralized bidding transactions [1] - The total number of shares held by the shareholders decreased from 26.9461 million shares to 26.6481 million shares, reducing their ownership from 14.08% to 13.92% of the company's total share capital, crossing the 1% threshold [1]